SVRA - サバラ （Savara Inc.） サバラSVRAのチャート
SVRAの企業情報
| symbol | SVRA |
|---|---|
| 会社名 | Savara Inc （サバラ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Savara Inc. formerly Mast Therapeutics Inc. is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial. サバラは米国のバイオ医薬品企業。臨床段階で、致命的な病気や重病に対する医薬品の開発に従事する。同社は心臓麻痺の治療用の医薬品候補として、噴霧状の亜硝酸ナトリウム「AIR001」や、浄化されたPoloxamer 188である「Velopoxamer」を開発する。本社はカリフォルニア州サンディエゴ。 savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com |
| 本社所在地 | 6836 Bee Cave Road Building III Suite 200 Austin TX 78746 USA |
| 代表者氏名 | Robert N. Neville ロバート・N・ネヴィル |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 512-614-1848 |
| 設立年月日 | 35034 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 24人 |
| url | www.masttherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/svra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -37.52100 |
| 終値（lastsale） | 10.34 |
| 時価総額（marketcap） | 362874793.16 |
| 時価総額 | 時価総額（百万ドル） 333.04460 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 273.60560 |
| 当期純利益 | 当期純利益（百万ドル） -54.56400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Savara Inc revenues was not reported. Net loss applicable to common stockholders increased from $17.5M to $38.4M. Higher net loss reflects Impairment of acquired IPR&D increase from $0K to $21.7M (expense) Research and development - Balancing val increase from $7M to $17.4M (expense) Stock-based Compensation in R&D increase from $74K to $373K (expense). |
SVRAのテクニカル分析
SVRAのニュース
Savara to Present at the Jefferies Healthcare Conference 2023/06/02 12:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s
Why Shares of Savara Jumped on Tuesday 2023/05/16 16:32:00 The Motley Fool
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Savara rises as Jefferies upgrades citing 100% upside 2023/05/16 13:25:00 Seeking Alpha
Savara (SVRA) shares gained Tuesday after Jefferies upgraded it to Buy citing over 100% upside from a positive Phase 3 readout for its lead asset. Read more here.
Jefferies downgrades Savara to Hold 2023/04/03 12:52:35 Investing.com
https://www.investing.com/news/pro/mast-therapeutics-receives-investment-bank-analyst-rating-update-3047692
Savara GAAP EPS of -$0.07 2023/03/31 04:32:20 Seeking Alpha
Savara press release (SVRA): Q4 GAAP EPS of -$0.07.As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million.
Zomato deputy CFO Savara quits 2022/08/31 20:12:33 Livemint
Savara’s exit comes a year after Zomato co-founder Gaurav Gupta quit expressing his desire to pursue his own venture
Savara''s rare lung disorder drug gets promising innovative medicine status in UK 2022/08/26 10:11:08 Seeking Alpha
Savara (SVRA) said on Aug. 25 that the U.K.''s Medicines and Healthcare Products Regulatory Agency ((MHRA)) granted promising innovative medicine ((PIM)) designation to molgramostim…
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) 2022/08/25 12:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to molgramostim for the treatment of aPAP, a rare lung disease with no approved pharmaceutical treatments. PIM designation is an early indication that molgramostim is a promising candidate for the EAMS, a program
Recap: Savara Q2 Earnings 2022/08/12 04:28:04 Benzinga
Savara (NASDAQ: SVRA ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Savara reported in-line EPS of $-0.06 versus … Full story available on Benzinga.com
Savara GAAP EPS of -$0.06 in-line (NASDAQ:SVRA) 2022/08/11 21:12:01 Seeking Alpha
Savara press release (SVRA): Q2 GAAP EPS of -$0.06 in-line.“Despite ongoing factors such as geographical COVID surges, geopolitical issues and supply chain constraints, IMPALA-2,…
Savara enters into $26.5M debt refinancing agreement with Silicon Valley Bank 2022/04/22 12:56:02 Seeking Alpha
Savara entered into a $26.5M term loan agreement with Silicon Valley Bank to replace its existing credit facility with the bank.
Savara GAAP EPS of -$0.07 in-line 2022/03/30 21:20:37 Seeking Alpha
Savara press release (SVRA): Q4 GAAP EPS of -$0.07 in-line.As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of $161.2 million.
Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update 2022/03/30 20:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business update. “The company underwent a significant amount of positive change in 2021. We streamlined the pipeline to focus solely on the molgramostim development program, strengthened our management team with key hires in clinical, regulatory, and CMC and improved our financial position with a $130M
Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference 2022/03/09 13:05:00 Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical
Savara Inc (NASDAQ:SVRA) Director Acquires $28,250.00 in Stock 2021/12/20 11:10:42 Transcript Daily
Savara Inc (NASDAQ:SVRA) Director David A. Ramsay acquired 25,000 shares of the companys stock in a transaction dated Friday, December 17th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $28,250.00. The purchase was disclosed in a legal filing with the SEC, which is available at the []